<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01392235</url>
  </required_header>
  <id_info>
    <org_study_id>FMTN-II-NPC</org_study_id>
    <nct_id>NCT01392235</nct_id>
  </id_info>
  <brief_title>Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC)</brief_title>
  <official_title>A Single-arm, Open, Multicenter, Phase II Study of Famitinib as ≥Third Line Treatment in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3,&#xD;
      Flt1 and Flt3. Phase I study has shown that the drug's toxicity is manageable.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well famitinib works in treating patients with&#xD;
      recurrent and/or metastatic NPC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2011</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CBR(Clinical Benefit Rate)</measure>
    <time_frame>12 weeks</time_frame>
    <description>To evaluate the efficacy (clinical benefit rate) of single-agent famitinib in patients with recurrent or metastatic NPC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR (Objective Response Rate)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS(Progress Free Survival)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR(Disease Control Rate)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS(Sverall Survival)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and tolerability</measure>
    <time_frame>3 years</time_frame>
    <description>Number of participants with adverse events and serious adverse events.In addition,estimating their relationship with Famitinib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL(Quality of Life)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Recurrent Nasopharyngeal Carcinoma</condition>
  <condition>Metastatic Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Drug: Famitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Famitinib</intervention_name>
    <description>25 mg qd p.o. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent</description>
    <arm_group_label>Drug: Famitinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologic confirmed recurrent and/or metastatic nasopharyngeal&#xD;
             carcinoma( NPC )&#xD;
&#xD;
          -  Have failed for ≥2 lines of chemotherapy&#xD;
&#xD;
          -  At least one measurable lesion, larger than 10 mm in diameter by spiral CT&#xD;
             scan(scanning layer ≤ 5 mm )&#xD;
&#xD;
          -  ≥ 18 and ≤ 70 years of age&#xD;
&#xD;
          -  ECOG performance scale 0-2&#xD;
&#xD;
          -  Life expectancy of more than 3 months&#xD;
&#xD;
          -  More than 4 weeks after operation, chemotherapy, radiotherapy, cytotoxic agents or&#xD;
             tyrosine kinase inhibitors&#xD;
&#xD;
          -  Adequate hepatic, renal, heart, and hematologic functions (hemoglobin ≥ 90g/L,&#xD;
             platelets ≥ 80×10^9/L, neutrophils ≥ 1.5×10^9/L, 24-hour urinary protein ≤ 1.0 g total&#xD;
             bilirubin &lt; 1.25×the upper limit of normal(ULN), and serum transaminase &lt; 1.5×the ULN&#xD;
             (If liver metastases, serum transaminase&lt; 2.5×the ULN), serum creatine ≤ 1x ULN,&#xD;
             creatinine clearance rate &gt; 50ml/min, Cholesterol≤7.75 mmol/L and triglyceride≤2.5 x&#xD;
             ULN, LVEF: ≥ 50%&#xD;
&#xD;
          -  Patients could provide 4-6 pieces of organization wax or pathological section&#xD;
&#xD;
          -  Female: All subjects who are not surgically sterile or postmenopausal must agree and&#xD;
             commit to the use of a reliable method of birth control for the duration of the study&#xD;
             and for 6 months after the last dose of test article. Child bearing potential, a&#xD;
             negative urine or serum pregnancy test result before initiating Famitinib. Male: All&#xD;
             subjects who are not surgically sterile or postmenopausal must agree and commit to the&#xD;
             use of a reliable method of birth control for the duration of the study and for 6&#xD;
             months after the last dose of test article.&#xD;
&#xD;
          -  Signed and dated informed consent. Willingness and ability to comply with scheduled&#xD;
             visits, treatment plans, laboratory tests, and other study procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior therapy with tyrosine kinase -inhibitor agent targeting at VEGFR, PDGFR and&#xD;
             c-Kit&#xD;
&#xD;
          -  Prior radiotherapy more than 2 courses&#xD;
&#xD;
          -  Before or at the same time any, second malignancies except cured basal cell carcinoma&#xD;
             of skin and carcinoma in-situ of uterine cervix&#xD;
&#xD;
          -  Less than 4 weeks from the last clinical trial&#xD;
&#xD;
          -  Any factors that influence the usage of oral administration&#xD;
&#xD;
          -  Known Spinal Cord compression or diseases of brain or pia mater by CT /MRI screening&#xD;
&#xD;
          -  Imageology shows that tumor lesion less than 5 mm to great vessels&#xD;
&#xD;
          -  Preexisting uncontrolled hypertension defined as more than 140/90 mmHg despite using&#xD;
             single medical therapy, more than cla ss I (NCI CTCAE 3.0 ) myocardial ischemia,&#xD;
             arrhythmia, or cardiac insufficiency&#xD;
&#xD;
          -  URT: urine protein ≥ ++ and &gt; 1.0 g of 24 h&#xD;
&#xD;
          -  Long-term untreated wounds or fractures&#xD;
&#xD;
          -  Blood coagulation abnormal, having hemorrhagic tendency (eg. active peptic ulcer&#xD;
             disease) or receiving the therapy of thrombolysis or anticoagulation.&#xD;
&#xD;
          -  Within 6 months before the first treatment occurrs artery / venous thromboembolic&#xD;
             events, such as cerebral vascular accident (including transient ischemic attack), deep&#xD;
             vein thrombosis and pulmonary embolism, etc.&#xD;
&#xD;
          -  Application of anticoagulants or vitamin K antagonists such as warfarin, heparin or&#xD;
             its analogues; If the prothrombin time international normalized ratio (INR) ≤ 1.5,&#xD;
             with the purpose of prevention, the use of small doses of warfarin (1mg orally, once&#xD;
             daily) or low-dose aspirin (between 80mg to 100mg daily) is allowed&#xD;
&#xD;
          -  Preexisting thyroid dysfunction, even using medical therapy, thyroid function cannot&#xD;
             maintain in the normal range&#xD;
&#xD;
          -  Abuse of Psychiatric drugs or dysphrenia&#xD;
&#xD;
          -  Viral hepatitis type B or type C&#xD;
&#xD;
          -  Immunodeficiency: HIV positive, or other acquired immunodeficiency, congenital&#xD;
             immunodeficiency, or organ transplantation&#xD;
&#xD;
          -  Evidence of significant medical illness that in the investigator's judgment will&#xD;
             substantially increase the risk associated with the subject's participation in and&#xD;
             completion of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Medical Oncology, Cancer Center, Sun Yet-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>July 3, 2011</study_first_submitted>
  <study_first_submitted_qc>July 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2011</study_first_posted>
  <last_update_submitted>January 17, 2019</last_update_submitted>
  <last_update_submitted_qc>January 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

